Linked Life Data

20211577

Source:http://linkedlifedata.com/resource/pubmed/id/20211577

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2-3
pubmed:dateCreated
2010-6-4
pubmed:abstractText
The experimental infectivity and excellent tolerance of some rodent autonomous parvoviruses in humans, together with their oncosuppressive effects in preclinical models, speak for the inclusion of these agents in the arsenal of oncolytic viruses under consideration for cancer therapy. In particular, wild-type parvovirus H-1PV can achieve a complete cure of various tumors in animal models and kill tumor cells that resist conventional anticancer treatments. There is growing evidence that H-1PV oncosuppression involves an immune component in addition to the direct viral oncolytic effect. This article summarizes the recent assessment of H-1PV antineoplastic activity in glioma, pancreatic ductal adenocarcinoma, and non-Hodgkin lymphoma models, laying the foundation for the present launch of a first phase I/IIa clinical trial on glioma patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1879-0305
pubmed:author
pubmed:copyrightInfo
2010 Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
21
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
185-95
pubmed:meshHeading
pubmed:articleTitle
Oncolytic parvoviruses as cancer therapeutics.
pubmed:affiliation
Division of Tumor Virology, German Cancer Research Center, and Cancer Virotherapy Unit, French National Institute of Health and Medical Research, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany. j.rommelaere@dkfz.de
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't